relaxin

Description Results NMA

48-h intravenous infusions of placebo or serelaxin (30 ìg/kg per day) within 16 h from presentation (n=-9)

vs.

placebo (on top stnadard care) (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

intravenous relaxin for 48 hours: 10µg/kg daily, 30µg/kg daily, 100µg/kg daily, 250µg/kg daily (n=172)

vs.

placebo (n=62)

double blind

Parallel groups

Sample size: 172/62

Primary endpoint: none defined

FU duration:

dose-finding phase IIb study